The BTK inhibitors and venetoclax have revolutionized the treatment of CLL, with “cure” or long-term treatment-free remission now seeming a realistic goal, although RT remains a formidable therapeutic challenge. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.